Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This entry refers to a novel antisense transcript annotated as non-coding RNA overlapping RANBP3. Its sequence is registered in the Ensembl genome database (ENSG00000302284) as antisense to the RANBP3 gene, but there is currently no functional characterization, evidence of protein coding, or implication in diseases. It does not meet criteria for therapeutic target classification and is unlikely to have direct biomedical relevance outside of potential regulation of RANBP3 expression at the RNA level[5]. ENSG00000302284 is an annotated non-coding antisense transcript to RANBP3 with no known protein product, molecular function, or therapeutic relevance[5]. This makes the target designation incorrect for structured drug discovery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to RANBP3 (ENSG00000302284).